• SPX
  • $5,958.67
  • 0.17 %
  • $9.96
  • DJI
  • $44,237.90
  • 0.84 %
  • $367.54
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,977.62
  • 0.03 %
  • $5.20
App Store Download on the App Store Google Play GET IT ON Google Play

Get The App

App Store Download on the App Store Google Play GET IT ON Google Play
Myriad Genetics, Inc. (MYGN) Stock Price, News & Analysis

Myriad Genetics, Inc. (MYGN) Stock Price, News & Analysis

Currency in USD Disclaimer

$15.60

$0.48

(3.17%)

Day's range
$15.1
Day's range
$15.67
50-day range
$14.72
Day's range
$29.3
  • Country: US
  • ISIN: US62855J1043
52 wk range
$14.72
Day's range
$29.3


We are preparing, please wait

1 Hour 1 Day 1 Week 1 Year Advanced Chart
Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.96
  • Piotroski Score 3.00
  • Grade Neutral
  • Symbol (MYGN)
  • Company Myriad Genetics, Inc.
  • Price $15.60
  • Changes Percentage (3.17%)
  • Change $0.48
  • Day Low $15.10
  • Day High $15.67
  • Year High $29.30

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 07/01/2009
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $29.00
  • High Stock Price Target $35.00
  • Low Stock Price Target $22.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.80
  • Trailing P/E Ratio -7.91
  • Forward P/E Ratio -7.91
  • P/E Growth -7.91
  • Net Income $-112,000,000

Income Statement

Quarterly

Annual

Latest News of MYGN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

View ALL
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Myriad Genetics, Inc. Frequently Asked Questions

  • What were the earnings of MYGN in the last quarter?

    In the last quarter Myriad Genetics, Inc. earnings were on Thursday, November, 7th. The Myriad Genetics, Inc. maker reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.04.

  • What is the Myriad Genetics, Inc. stock price today?

    Today's price of Myriad Genetics, Inc. is $15.60 — it has increased by +3.17% in the past 24 hours. Watch Myriad Genetics, Inc. stock price performance more closely on the chart.

  • Does Myriad Genetics, Inc. release reports?

    Yes, you can track Myriad Genetics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Myriad Genetics, Inc. stock forecast?

    Watch the Myriad Genetics, Inc. chart and read a more detailed Myriad Genetics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Myriad Genetics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Myriad Genetics, Inc. stock ticker.

  • How to buy Myriad Genetics, Inc. stocks?

    Like other stocks, MYGN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Myriad Genetics, Inc.'s EBITDA?

    Myriad Genetics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Myriad Genetics, Inc.’s financial statements.

  • What is the Myriad Genetics, Inc.'s net income ratio for the financial year 2022?

    The net income ratio for the financial year 2022 is -0.1650943396, which equates to approximately -16.51%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Myriad Genetics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Myriad Genetics, Inc.'s financials relevant news, and technical analysis. Myriad Genetics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Myriad Genetics, Inc. stock currently indicates a “sell” signal. For more insights, review Myriad Genetics, Inc.’s technical analysis.

  • A revenue figure for Myriad Genetics, Inc. for its last quarter?

    Myriad Genetics, Inc. published it's last quarterly revenues at $191.90 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

or
download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Sign Up With Email Address
or
google app download Continue with Google ios app download Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.